ASX-listed healthcare technology company Lifespot Health is planning to conduct extensive clinical trials in 2021 to meet the TGA safety and efficacy standards required for medical registration of its combined medical inhaler/cannabinoid e-liquid products.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lifespot Health CEO Matthew Golden said he expects the trials will demonstrate greater cost effectiveness for patients and could lead to CBD vapes being available over the counter at pharmacies in the foreseeable future.